Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Methylphenidate as Needed for Fatigue in Patients With Advanced Cancer. A Prospective, Double-Blind, and Placebo-Controlled Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Causes of hospital admissions in Domus: a randomized controlled trial of specialized palliative cancer care at home

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Comparison of EORTC QLQ-C30 and PRO-CTCAE™ Questionnaires on Six Symptom Items

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Stability and Priority of Symptoms and Symptom Clusters Among Allogeneic HSCT Patients Within a 5-Year Longitudinal Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Thyroid function in COVID-19 and the association with cytokine levels and mortality

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Characteristics of patients reporting symptoms by open-ended questions in specialist palliative care

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

CONTEXT: Cancer-related fatigue is a highly prevalent symptom with a strong negative impact on patients' daily life.

OBJECTIVES: To evaluate the efficacy of methylphenidate as needed for the management of fatigue in patients with advanced cancer.

METHODS: A prospective, controlled, double-blind, and paired design, where the patient was her and/or his own control. Patients with advanced cancer with a tiredness score of ≥50 on a 0-100 visual analogue scale (VAS) were included. Patients were given 10 placebo and 10 methylphenidate tablets numbered 1-20 packed in blocks of four with two active and two placebo tablets (randomly arranged). Patients taking minimum three tablets were regarded evaluable. Primary effect parameters were mean differences in VAS for tiredness after two and five hours. With 28 evaluable patients, the study had a power of 0.90 to detect a mean difference of 15 between active and placebo.

RESULTS: Thirty-eight patients were enrolled to get 28 evaluable patients. Mean tiredness score before taking the tablets was 75 for placebo and 72 for methylphenidate on VAS (0-100). Mean changes (decrease) for methylphenidate after two and five hours were 20 and 17, respectively, and eight and five for placebo. Comparing mean differences, a significant decrease for methylphenidate compared with placebo was observed after two hours (P = 0.004) and five hours (P = 0.001), respectively.

CONCLUSION: In this controlled and double-blind study in patients with advanced cancer, methylphenidate as needed was significantly more effective than placebo in relieving fatigue after two and five hours.

OriginalsprogEngelsk
TidsskriftJournal of Pain and Symptom Management
Vol/bind60
Udgave nummer5
Sider (fra-til)992-1002
Antal sider11
ISSN0885-3924
DOI
StatusUdgivet - nov. 2020

Bibliografisk note

Copyright © 2020 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.

ID: 61360827